BioPharmSignal logoBioPharmSignal

Biotech News

Notice of Half-Yearly Results

PureTech Health (PRTC)PureTech HealthCompany update

RNS Number: 4123T PureTech Health PLC 04 September 2026 4 September 2026 PureTech Health plc Notice of Half-Yearly Results PureTech Health plc (LSE: PRTC) (" PureTech " or the "Company") plans to announce its half-yearly results for the six months ended 30 June 2026 on Tuesday 22 September 2026.

Related news

PRTCPureTech Health2026-09-22 06:00 EST

PureTech Health plc – Half-Year Report

PRTCPureTech Health2026-04-13 06:05 EST

PureTech Health plc Notice of Results

View all latest news

PureTech Health

Founded-Entity Model PureTech Health creates and advances biotechnology companies around internally identified scientific concepts. Rather than operating as a conventional single-pipeline developer, it retains ownership interests and economic rights across a portfolio of independently financed founded entities. Celea Therapeutics Celea...

Recent company news

PRTCPureTech Health2026-10-07 17:00 EST

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance

PRTCPureTech Health2026-09-22 06:00 EST

PureTech Health plc – Half-Year Report

PRTCPureTech Health2026-09-21 06:00 EST

PureTech Announces Successful End-of-Phase 1 Meeting with U.S . Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)

PRTCPureTech Health2026-09-09 17:00 EST

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

PRTCPureTech Health2026-09-04 06:00 EST

Notice of Half-Yearly Results

Stock data

Close
17.42 USD
Market cap
424.03M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States